The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | An introduction to the MAPK signaling pathway and pan-RAF inhibitors
Rajwanth Veluswamy, MD, Icahn School Of Medicine At Mount Sinai, New York, NY, gives an overview of the MAPK signaling pathway in cancer and the development of pan-RAF inhibitors. The MAPK pathway consists of various protein kinases and the most common mutation seen in lung cancer is the V600E mutation in BRAF. Overall, BRAF mutations can be divided into class I, II or III, where V600E mutations fall into class I mutations. Pan-RAF inhibitors do not target specific BRAF mutations and are currently under investigation in clinical trials. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
